Five things for pharma marketers to know for Tuesday, September 23, 2025

['.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright', 'Display Table .Wp-Block-Co-Authors-Plus-Avatar.Aligncenter Display Table Margin-Inline Auto'] News Archive - MM+M - Medical Marketing and Media 2025-09-24 04:38:38

(Reuters)Roche is set to launch a late-stage trial of an experimental obesity drug in 2026. Compared to a 2011 study, fewer doctors believe accepting gifts under $50 from drug companies is problematic. (STAT News)The Food and Drug Administration rejected Otsuka’s and Lundbeck’s Rexulti and Zoloft combination drug. (Endpoints News)Pfizer boosted its obesity drug prospects with a deal worth up to $7.3 billion to buy Metsera. (CNBC)To read yesterday’s edition of Five things for pharma marketers to know, click here.